GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Dianthus Therapeutics Inc (NAS:DNTH) » Definitions » Pre-Tax Income

Dianthus Therapeutics (Dianthus Therapeutics) Pre-Tax Income : $-39.07 Mil (TTM As of Mar. 2024)


View and export this data going back to 2023. Start your Free Trial

What is Dianthus Therapeutics Pre-Tax Income?

Pretax income is the income that a company earns before paying income taxes. Dianthus Therapeutics's pretax income for the three months ended in Mar. 2024 was $-13.75 Mil. Its pretax income for the trailing twelve months (TTM) ended in Mar. 2024 was $-39.07 Mil. Dianthus Therapeutics's pretax margin was -1,573.00%.

During the past 3 years, Dianthus Therapeutics's highest Pretax Margin was -443.76%. The lowest was -1732.77%. And the median was -888.14%.

Dianthus Therapeutics Pre-Tax Income Historical Data

The historical data trend for Dianthus Therapeutics's Pre-Tax Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Dianthus Therapeutics Pre-Tax Income Chart

Dianthus Therapeutics Annual Data
Trend Dec21 Dec22 Dec23
Pre-Tax Income
-13.11 -28.48 -43.56

Dianthus Therapeutics Quarterly Data
Dec21 Sep22 Dec22 Mar23 Sep23 Dec23 Mar24
Pre-Tax Income Get a 7-Day Free Trial -10.12 -7.09 -14.76 -10.56 -13.75

Competitive Comparison of Dianthus Therapeutics's Pre-Tax Income

For the Biotechnology subindustry, Dianthus Therapeutics's Pre-Tax Income, along with its competitors' market caps and Pre-Tax Income data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Dianthus Therapeutics's Pre-Tax Income Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Dianthus Therapeutics's Pre-Tax Income distribution charts can be found below:

* The bar in red indicates where Dianthus Therapeutics's Pre-Tax Income falls into.


Dianthus Therapeutics Pre-Tax Income Calculation

This is the income that a company earns before paying income taxes.

Dianthus Therapeutics's Pretax Income for the fiscal year that ended in Dec. 2023 is calculated as

Pretax Income=Operating Income+Non Operating Income+Interest Expense+Interest Income+Other
=-48.174+-0.145+0+4.764+0
=-43.56

Dianthus Therapeutics's Pretax Income for the quarter that ended in Mar. 2024 is calculated as

Pretax Income=Operating Income+Non Operating Income+Interest Expense+Interest Income+Other
=-17.844+-0.126+0+4.222+1.7763568394003E-15
=-13.75

Pre-Tax Income for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-39.07 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Dianthus Therapeutics  (NAS:DNTH) Pre-Tax Income Explanation

Dianthus Therapeutics's Pretax Margin for the quarter that ended in Mar. 2024 is calculated as

Pretax Margin=Pretax Income/Revenue
=-13.748/0.874
=-1,573.00%

During the past 3 years, Dianthus Therapeutics's highest Pretax Margin was -443.76%. The lowest was -1732.77%. And the median was -888.14%.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Dianthus Therapeutics Pre-Tax Income Related Terms

Thank you for viewing the detailed overview of Dianthus Therapeutics's Pre-Tax Income provided by GuruFocus.com. Please click on the following links to see related term pages.

Dianthus Therapeutics (Dianthus Therapeutics) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Dianthus Therapeutics Inc (NAS:DNTH) » Definitions » Pre-Tax Income
Comparable Companies
SELB INZY IKNA MACK CBUS PSTX ALVR STOK TCRX ATXS OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA XBRU:ARGX HKSE:02269 BNTX
Traded in Other Exchanges
87E:Germany
Address
7 Times Square, 43rd Floor, New York, NY, USA, 10036
Website
https://www.dianthustx.com
Dianthus Therapeutics Inc is a clinical-stage biotechnology company dedicated to designing and delivering novel, best-in-class monoclonal antibodies with improved selectivity and potency over existing complement therapies. The company is comprised of an experienced team of biotech and pharma executives who are leading the next generation of antibody complement therapeutics, aiming to deliver transformative medicines for people living with severe autoimmune diseases.

Dianthus Therapeutics (Dianthus Therapeutics) Headlines

From GuruFocus

Fairmount Funds Management LLC Acquires New Stake in Dianthus Therapeutics Inc

By GuruFocus Research • 09-29-2023

Insider Buying: Fairmount Funds Management LLC Acquires 24,254 Shares of Dianthus Therapeutics Inc

By GuruFocus Research • 09-14-2023